Gencor Nutrients to Present Fenugreek Male Libido Study Findings at SupplySide West
Next week at SupplySide West, Gencor Nutrients Inc. (Anaheim, CA) will present the results of a new human clinical study recently completed in Australia on male libido and Testofen, Gencor's proprietary extract of fenugreek. Gencor says that the study's results show Testofen to be a safe and effective product for increasing libido in healthy males.
Next week at SupplySide West, Gencor Nutrients Inc. (Anaheim, CA) will present the results of a new human clinical study recently completed in Australia on male libido and Testofen, Gencor's proprietary extract of fenugreek. Gencor says that the study's results show Testofen to be a safe and effective product for increasing libido in healthy males.
The randomized, double-blind placebo study tested sexual function, performance, and libido levels in 60 healthy males ranging between the ages of 21 and 50, over a six-week period. Gencor says that results showed that Testofen produced a significant positive change in all parameters of libido, including sexual cognition, sexual arousal, sexual experience, and orgasm.
The company adds that the effects may also be a result of interaction with testosterone via alpha-5 reductase activity.
Details of the study will be presented at SupplySide West in a VendorWorks seminar on November 13 at 2:30 p.m.
Balchem’s Newest Launch Optifolin+® Brings Innovation to the Folate Market
November 15th 2024Supplement launches featuring 5-MTHF are on the rise with double digit growth. In this episode of Nutritional Outlook’s podcast, we explore Optifolin+®, a new ingredient in the market that offers essential nutrition from prenatal through adulthood. Join us as we uncover the potential impact of the next evolution in folate, setting the stage for a healthier future.
The Nutritional Outlook Podcast Episode 35: Prioritizing Women's Health Research and Innovation
October 28th 2024On this month's episode of the Nutritional Outlook Podcast, Cepham's founder and president, Anand Swaroop, discusses the company's recent announcement to prioritize women's health research and innovation.
